Neuromuscular Disease News and Research

RSS
Muscular Dystrophy Association awards 44 research grants totaling $13.5 million

Muscular Dystrophy Association awards 44 research grants totaling $13.5 million

CMD co-founder receives Prize4Life award for discovery of new ALS biomarker

CMD co-founder receives Prize4Life award for discovery of new ALS biomarker

Research shows nestin regulates formation of neuromuscular junction

Research shows nestin regulates formation of neuromuscular junction

Genzyme to expand Geel facility to support growth of Myozyme and Lumizyme for Pompe disease

Genzyme to expand Geel facility to support growth of Myozyme and Lumizyme for Pompe disease

GSK and Prosensa commence GSK2402968 Phase III study in DMD

GSK and Prosensa commence GSK2402968 Phase III study in DMD

Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy

Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

SBUMC to rename and dedicate ALS clinic as Christopher Pendergast ALS Center of Excellence

SBUMC to rename and dedicate ALS clinic as Christopher Pendergast ALS Center of Excellence

Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

Radical change to Alzheimer’s management

Radical change to Alzheimer’s management

Comprehensive guide to current practice of intraoperative neurophysiology

Comprehensive guide to current practice of intraoperative neurophysiology

28% of health care workers in 'work risk' category will not get flu vaccine

28% of health care workers in 'work risk' category will not get flu vaccine

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

FDA designates NeuRx Diaphragm Pacing System as HUD device for ALS patients

FDA designates NeuRx Diaphragm Pacing System as HUD device for ALS patients

Immune reaction to dystrophin may contribute to muscle disease: Study

Immune reaction to dystrophin may contribute to muscle disease: Study

ALS Society of Canada applauds Prime Minister's commitment to ensure benefits for veterans with ALS

ALS Society of Canada applauds Prime Minister's commitment to ensure benefits for veterans with ALS

Study finds genetic change in chromosome 4 causes FSHD

Study finds genetic change in chromosome 4 causes FSHD

Muscular Dystrophy Association awards $14.1M in new grants

Muscular Dystrophy Association awards $14.1M in new grants

FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD

FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD